NovoEight® (turoctocog alfa) Patient Information Leaflet
NovoEight® 250 IU
PIL

NovoEight® 500 IU
PIL

NovoEight® 1000 IU
PIL

NovoEight® 1500 IU
PIL

NovoEight® 2000 IU
PIL

NovoEight® 3000 IU
PIL
 
   
Summary of Product Characteristics - Click here

NovoSeven® (eptacog alfa activated)

Patient Information Leaflet

NovoSeven® 1mg

PIL

NovoSeven® 2mg

PIL

NovoSeven® 5mg

PIL

NovoSeven® 8mg

PIL

   
Summary of Product Characteristics - Click here

Refixia®    (nonacog beta pegol) Patient Information Leaflet

Refixia®     500 IU 

PIL  

Refixia®     1000 IU 
 
PIL  

Refixia®     2000 IU 
 
PIL  
     
Summary of Product Characteristics - Click here

Esperoct®  (turoctocog alfa pegol) Patient Information Leaflet    
Esperoct®    500 IU
PIL

Esperoct®   1000 IU
PIL

Esperoct®   1500 IU

PIL

Esperoct®   2000 IU
PIL

Esperoct®   3000 IU
PIL

   
Summary of Product Characteristics - Click here

 

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side-effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.  

Adverse events should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0800 023 2573).  Calls may be monitored for training purposes.

  This medicine is subject to additional safety monitoring.  This will allow quick identification of new safety information.  You can help by reporting any side effects you may get.  See mhra.gov.uk/yellowcard for how to report side effects.

This page is intended for members of the UK public